Abstract |
Diabetic macular edema (DME) and proliferative retinopathy are common causes for blindness in middle-aged patients. The gold standard for treatment has been laser coagulation. Limitations of this therapy are refractive DME, ischaemic diabetic maculopathy and complications after laser application. The need for a non-destructive and effective strategy has led to investigations regarding vascular endothelial growth factor ( VEGF) inhibitors for reduction of vessel leakage and oedema formation. VEGF antibody fragments have been approved for age-associated macular degeneration (AMD) in different countries and have proved to be safe and effective. Trials for different anti- VEGF compounds are nearing completion or are completed. Published data show a superiority of anti- VEGF therapy compared to laser coagulation. In the present article, data regarding dose, injection scheme and practicable application form are reviewed.
|
Authors | V Kakkassery, S Winterhalter, A M Joussen |
Journal | Klinische Monatsblatter fur Augenheilkunde
(Klin Monbl Augenheilkd)
Vol. 227
Issue 9
Pg. 701-11
(Sep 2010)
ISSN: 1439-3999 [Electronic] Germany |
Vernacular Title | Die Rolle der Anti-VEGF-Therapie in der Behandlung des diabetischen Makulaödems. |
PMID | 20845250
(Publication Type: Journal Article, Review)
|
Copyright | © Georg Thieme Verlag KG Stuttgart · New York. |
Chemical References |
- Angiogenesis Inhibitors
- Antibodies, Monoclonal
- Antibodies, Monoclonal, Humanized
- Aptamers, Nucleotide
- Recombinant Fusion Proteins
- VEGFA protein, human
- Vascular Endothelial Growth Factor A
- aflibercept
- Triamcinolone
- pegaptanib
- Bevacizumab
- Receptors, Vascular Endothelial Growth Factor
- Ranibizumab
|
Topics |
- Angiogenesis Inhibitors
(administration & dosage, adverse effects)
- Antibodies, Monoclonal
(administration & dosage, adverse effects)
- Antibodies, Monoclonal, Humanized
- Aptamers, Nucleotide
(administration & dosage, adverse effects)
- Bevacizumab
- Blood-Retinal Barrier
(drug effects)
- Capillary Permeability
(drug effects)
- Clinical Trials as Topic
- Combined Modality Therapy
- Diabetic Retinopathy
(classification, diagnosis, drug therapy)
- Fluorescein Angiography
- Humans
- Intravitreal Injections
- Laser Coagulation
(adverse effects)
- Macular Edema
(classification, diagnosis, drug therapy)
- Middle Aged
- Off-Label Use
- Ranibizumab
- Receptors, Vascular Endothelial Growth Factor
- Recombinant Fusion Proteins
(administration & dosage, adverse effects)
- Retinoscopy
- Triamcinolone
(administration & dosage)
- Vascular Endothelial Growth Factor A
(antagonists & inhibitors)
|